🔗 Share this article

As America undertakes unprecedented revisions to its immunization schedules, one figure has emerged somewhat surprisingly: Høeg, a Danish American physician and epidemiologist who rose to prominence by casting doubt on coronavirus shots in the global health crisis and has concentrated on potential deaths after COVID-19 immunization in her short time at the Food and Drug Administration.

Planned Overhauls to Childhood Immunization Program

Health officials planned to announce radical changes to the childhood vaccine schedule in December, aligning the US with Denmark’s national calendar, according to reports – a significant shift that would place the US out of alignment with much of the world with no evidence for public health gain. The planned update has been delayed until the coming year.

In place of the director of the vaccine center, Tracy Beth Høeg is set to speak at the meeting. She was recently named interim head of the FDA’s CDER, the fifth individual to head the center this year.

A New Direction at the Agency

This interim role might represent a tighter collaboration between the pharmaceutical and biologics centers as Dr. Høeg and Dr. Prasad solidify control at the agency – and it suggests a increased emphasis upon rolling back already-approved vaccines at the FDA.

Høeg has repeatedly called for ending certain pediatric immunization guidelines in the US to become more like Denmark's approach, a country with comprehensive healthcare and a number of inhabitants about the population of Wisconsin’s.

To date statements, she has kept her attention on vaccines – traditionally the purview of Prasad, chief of the FDA’s CBER – rather than pharmaceutical oversight.

Questions Over Background

Høeg has little discernible background in medication creation, oversight or leadership, which has been customary for past leaders of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the commissioner and CBER since earlier this year.

“It seems she lacks to have the necessary background” for overseeing the pharmaceutical oversight division, stated Dr. Jonathan Howard. “She’s never run a clinical trial. She is not versed in leading a major agency. She is not an expert in pharmaceutical oversight.”

Past directors of the center would “understand regulatory frameworks and the science of medication creation”, commented Janet Woodcock. “Frankly, she has not acquired the kind of background that previous people who led CBER have had.”

The drug center has an immense range of responsibilities at the FDA, the former commissioner pointed out.

“Many people just focuses on the novel medication approvals, but the generic drug division approves numerous off-brand pharmaceuticals. There’s a biologic copycat branch, over-the-counter program and so forth, and every single one need to be supervised,” she explained. “The area you don’t keep your eye on, that is the part that I always told people is going to come back to haunt you.”

Additionally, a significant management element to the role, which supervises over 5,000 employees. “It’s a enormous administrative position, if you do it right,” she added.

Agency Reaction and Contentious Programs

When asked about questions about Dr. Høeg's fitness for the role and whether this selection indicates more teamwork among regulatory chiefs on immunizations, a press secretary responded that the “concerns rely on flawed premises”.

“This background aligns with the responsibilities of her position,” the spokesperson explained, noting the months Dr. Høeg spent counseling the agency head on “pharmaceutical safety and approval science, including predictive safety algorithms and shot safety tracking”.

In her interim role, Høeg takes over the agency head's controversial expedited review system, a contentious expedited medication authorization process that allegedly troubled her former heads. “By what process are these medications being chosen for this fast-track system? Who takes the calls?” Dr. Howard said. “There is a lot of confidentiality going on at the agency right now.”

Broadly speaking, he said, “the Food and Drug Administration seems to be moving towards laxer regulations of most medications, except for vaccines.”

Established Past Work on Vaccines

Regarding vaccines, Dr. Høeg has a more established, if concerning, history, some experts observe. She published a analysis using unverified volunteer-provided data to estimate the rate of myocarditis after Covid immunization. She consulted for the state of Florida surgeon general Dr. Joseph Ladapo, who reportedly have altered data to suggest COVID-19 vaccines are more dangerous than they are.

Among her “policy goals” for the incoming federal leadership included changing rules for novel immunizations and ending “non-essential” vaccines, she stated post-election on a podcast. At the FDA, Høeg has according to sources proposed excluding teenage boys from receiving Covid vaccines.

“She’s an thorough dogmatist who starts off with her conclusions and reverse-engineers to retrofit the data in a highly misleading, dishonest way,” Dr. Howard said.

Consolidating Power and a “Revenge Tour”

Dr. Høeg became part of other dissenters, {like|